These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 18068095

  • 1. Enhancement of antitumor activity of OK-432 (picibanil) by Triton X-114 phase partitioning.
    Hashimoto M, Takashige K, Furuyashiki M, Yoshidome K, Sano R, Kawamura Y, Ijichi S, Morioka H, Koide H, Oku N, Moriya Y, Kusumoto S, Suda Y.
    Int Immunopharmacol; 2008 Jan; 8(1):12-9. PubMed ID: 18068095
    [Abstract] [Full Text] [Related]

  • 2. Antitumor effect of OK-432-derived DNA: one of the active constituents of OK-432, a streptococcal immunotherapeutic agent.
    Oshikawa T, Okamoto M, Tano T, Sasai A, Kan S, Moriya Y, Ryoma Y, Saito M, Akira S, Sato M.
    J Immunother; 2006 Jan; 29(2):143-50. PubMed ID: 16531815
    [Abstract] [Full Text] [Related]

  • 3. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice.
    Mizushima Y, Morikage T, Hirata H, Sato M, Sakamoto K, Yano S.
    J Biol Response Mod; 1988 Aug; 7(4):371-83. PubMed ID: 3139841
    [Abstract] [Full Text] [Related]

  • 4. Down-regulation of IL-10 enhances the efficacy of locoregional immunotherapy using OK-432 against malignant effusion.
    Hihara J, Yamaguchi Y, Minami K, Noma K, Toge T.
    Anticancer Res; 1999 Aug; 19(2A):1077-84. PubMed ID: 10368657
    [Abstract] [Full Text] [Related]

  • 5. [Effect of combined immunotherapy using two different BRMs; OK-432 and IL-2-cultured lymphocytes].
    Kan N, Hori T, Ohgaki K, Inamoto T, Kodama H, Tobe T.
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1298-306. PubMed ID: 3488027
    [Abstract] [Full Text] [Related]

  • 6. Locoregional immunotherapy of malignant ascites from gastric cancer using DTH-oriented doses of the streptococcal preparation OK-432: Treatment of Th1 dysfunction in the ascites microenvironment.
    Yamaguchi Y, Ohshita A, Kawabuchi Y, Hihara J, Miyahara E, Noma K, Toge T.
    Int J Oncol; 2004 Apr; 24(4):959-66. PubMed ID: 15010836
    [Abstract] [Full Text] [Related]

  • 7. Involvement of nitric oxide in anti-tumor effects of OK-432, a streptococcal anti-tumor immunotherapeutic agent.
    Oshikawa T, Okamoto M, Tano T, Uddin Ahmed S, Sasai A, Kan S, Moriya Y, Ryoma Y, Saito M, Sato M.
    Int Immunopharmacol; 2006 May; 6(5):764-73. PubMed ID: 16546707
    [Abstract] [Full Text] [Related]

  • 8. [Immunobiological studies of interferon-alpha A/D in comparison with a streptococcal preparation, OK-432].
    Mizushima Y, Hirata H, Sakamoto K, Sato M, Morikage T, Maruyama M, Sasaki K, Yano S.
    Gan To Kagaku Ryoho; 1987 Sep; 14(9):2710-5. PubMed ID: 3631971
    [Abstract] [Full Text] [Related]

  • 9. [Antitumor effect of OK-432 (1)--antitumor effect of OK-432 induced interferon-gamma (IFN gamma)].
    Saito M, Yamaguchi T, Aonuma E, Noda T, Edina T, Ishida N.
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):2031-7. PubMed ID: 6820888
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432.
    Ono T, Harada M, Yamada A, Tanaka M, Takao Y, Tanaka Y, Mine T, Sakamoto K, Nakashima T, Itoh K.
    Clin Cancer Res; 2006 Feb 15; 12(4):1325-32. PubMed ID: 16489090
    [Abstract] [Full Text] [Related]

  • 14. Effect of streptococcal lyzate OK-432 on peripheral blood mononuclear cells in gastric cancer patients.
    Nakayama F, Iwagaki H, Gouchi A, Hizuta A, Isozaki H, Takakura N, Tanaka N.
    J Med; 1998 Feb 15; 29(3-4):199-215. PubMed ID: 9865458
    [Abstract] [Full Text] [Related]

  • 15. Effect of intratumoral OK-432 administration of thymidine phosphorylase expression in human gastric carcinoma.
    Ogawa K, Konno S, Takebayashi Y, Murayama M, Shimakawa T, Katsube T, Naritaka Y, Kajiwara T, Aiba M, Akiyama S.
    Anticancer Res; 2001 Feb 15; 21(2B):1257-62. PubMed ID: 11396196
    [Abstract] [Full Text] [Related]

  • 16. [Anticancer effects of OK-432 (2). Anticancer actions of M phi activated by OK-432].
    Saito M, Aonuma E, Noda T, Nakadate I, Nanjo M, Ebina T, Ishida N.
    Gan To Kagaku Ryoho; 1983 May 15; 10(5):1363-71. PubMed ID: 6870302
    [Abstract] [Full Text] [Related]

  • 17. Cytokine-inducing activity and antitumor effect of a liposome-incorporated interferon-gamma-inducing molecule derived from OK-432, a streptococcal preparation.
    Okamoto M, Gohda H, Ohe G, Yoshida H, Matsuno T, Saito M, Sato M.
    J Immunother; 2000 Jan 15; 23(1):94-103. PubMed ID: 10687142
    [Abstract] [Full Text] [Related]

  • 18. [Immunopotentiation by OK-432 ointment to apply to the mouse abdominal skin].
    Matsuoka H, Yano K, Baba H, Kounoe S, Seo Y, Saito T, Tomoda H, Wakasugi H.
    Gan To Kagaku Ryoho; 1995 Sep 15; 22(11):1644-6. PubMed ID: 7574783
    [Abstract] [Full Text] [Related]

  • 19. [Anti-tumor immunity induced by OK-432-derived DNA].
    Oshikawa T, Okamoto M, Ahmed SU, Tano T, Sasai A, Kan S, Sato M.
    Gan To Kagaku Ryoho; 2005 Oct 15; 32(11):1559-61. PubMed ID: 16315868
    [Abstract] [Full Text] [Related]

  • 20. TNF induces endogenous TNF in vivo: the basis of EET therapy as a combination of rTNF together with endogenous TNF.
    Inagawa H, Oshima H, Soma G, Mizuno D.
    J Biol Response Mod; 1988 Dec 15; 7(6):596-607. PubMed ID: 3216223
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.